NCT03931876 is a Phase 1 clinical trial of AV-006 in Bacterial Infections, sponsored by Arixa Pharmaceuticals.

Who is sponsoring NCT03931876?

NCT03931876 is sponsored by Arixa Pharmaceuticals.

What drugs are being tested in NCT03931876?

Interventions in NCT03931876: Placebos, AV-006.

What condition does NCT03931876 study?

NCT03931876 studies Bacterial Infections.

Is NCT03931876 still recruiting?

NCT03931876 is currently status unknown. Last updated 1 May 2019.

Last reviewed 2019-05-01 · How we verify

NCT03931876

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single Ascending Dose Study of AV-006 in Healthy Subjects

Status unknown Phase 1 Last updated 1 May 2019

What this trial tests

Phase 1 trial testing Placebos in Bacterial Infections in 40 participants. Status unknown.

Timeline

24 June 2019

Primary endpoint
1 September 2019

1 November 2019

Quick facts

Lead sponsor	Arixa Pharmaceuticals
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	40
Start date	24 June 2019
Primary completion	1 September 2019
Estimated completion	1 November 2019
Sites	1 location across Australia

Drugs / interventions tested

Placebos — full drug profile →
AV-006 — full drug profile →

Conditions studied

Bacterial Infections — all drugs for Bacterial Infections →

Sponsor

Arixa Pharmaceuticals — full company profile →

Who can join

Adults 18 to 55, any sex, with Bacterial Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Characterization of the single dose pharmacokinetics of AV-006 in healthy male and female subjects. Description of safety and tolerability of AV-006 in healthy subjects

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.
Miller WR, Arias CA. · · 2024 · cited 481× · PMID 38831030 · DOI 10.1038/s41579-024-01054-w
Antibiotics in the clinical pipeline in October 2019.
Butler MS, Paterson DL. · · 2020 · cited 174× · PMID 32152527 · DOI 10.1038/s41429-020-0291-8
Antibiotics in the clinical pipeline as of December 2022.
Butler MS, Henderson IR, Capon RJ, Blaskovich MAT. · · 2023 · cited 147× · PMID 37291465 · DOI 10.1038/s41429-023-00629-8
Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.
Negatu DA, Zimmerman MD, Dartois V, Dick T. · · 2022 · cited 26× · PMID 36047786 · DOI 10.1128/aac.00790-22
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.
Negatu DA, González Del Río R, Cacho-Izquierdo M, Barros-Aguirre D, et al · · 2023 · cited 15× · PMID 36688684 · DOI 10.1128/aac.01459-22
Antibacterials with Novel Chemical Scaffolds in Clinical Development.
Heimann D, Kohnhäuser D, Kohnhäuser AJ, Brönstrup M. · · 2025 · cited 10× · PMID 39847315 · DOI 10.1007/s40265-024-02137-x
The in vitro effect of new combinations of carbapenem-β-lactamase inhibitors for Mycobacterium abscessus.
Fröberg G, Ahmed A, Chryssanthou E, Davies Forsman L. · · 2023 · cited 8× · PMID 37671880 · DOI 10.1128/aac.00528-23
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli.
Le Terrier C, Nordmann P, Bouvier M, Poirel L. · · 2023 · cited 6× · PMID 37668385 · DOI 10.1128/aac.00547-23

Verify or expand the search:

Other recruiting trials for Bacterial Infections

Currently open trials in the same condition.

NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
NCT07104162 — A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal I · Phase 1 · recruiting
NCT07207291 — Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers · Phase 1 · recruiting
NCT07056881 — Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa · recruiting
NCT06592586 — A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women · Phase 2, PHASE3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03931876 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arixa Pharmaceuticals
Last refreshed: 1 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03931876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing